The NAP4DIVE Project

NAP4DIVE aims to reduce animal use in central nervous system drug development by up to 95% while saving 30% of costs. The project includes development of a non-animal platform for nanoparticle-based delivery across the blood–brain barrier interface with vehicle evolution. By combining advanced in vitro blood–brain barrier models with in silico design and optimization tools, NAP4DIVE enables more predictive, human-relevant assessment of nanoparticle performance. The platform is designed to accelerate CNS drug discovery while improving translational success and supporting ethical, animal-free innovation.

HansaBioMed Life Sciences is involved in the production and upscaling of nanoparticle manufacturing and quality control.

HansaBioMed Life Sciences, Åbo Akademi University, Finnadvance, AstraZeneca plc, The University of Gothenburg, Chalmers University of Technology, The Microfluidics Innovation Center, Delft University of Technology, Betthera s.r.o., AMIRES S.R.O. , Eindhoven University of Technology